Summary

Expands coverage of modern cancer diagnostic and lab tests across Medicare, Medicaid, and CHIP. It defines which genomic sequencing tests and their professional interpretation are covered, limits how often a person can receive them for the same cancer, and waives the Medicare deductible for these tests. States must ensure Medicaid and CHIP plans cover these tests starting January 1, 2027. Creates a national education and awareness effort on genomic testing, led by the Department of Health and Human Services with the National Human Genome Research Institute. The program targets both physicians and the public, and encourages medical training programs and continuing education (including oncology) to teach how molecular diagnostics help detect tumor mutations at diagnosis and when cancer returns.

Key Points

• Requires Medicare, Medicaid, and CHIP to cover defined cancer genomic sequencing tests and their interpretation.
• Limits how often a person can receive these tests for the same cancer to prevent unnecessary repeat testing.
• Waives the Medicare deductible for these cancer diagnostic and lab tests.
• Mandates Medicaid and CHIP coverage of these tests starting January 1, 2027.
• Creates a nationwide education and awareness effort on genomic testing for clinicians and the public.
• Encourages medical schools, residencies, fellowships, and continuing education to include molecular diagnostics training.
• Aims to improve use of tumor mutation testing at initial diagnosis and at cancer recurrence.
• Seeks to expand equitable access to precision oncology tools across public coverage programs.

Categories & Tags